Patents for A61P 35 - Antineoplastic agents (221,099)
04/2008
04/30/2008CN100384475C Preparation method of magnetic guiding anticancer medicine
04/30/2008CN100384472C Antigen-specific lgE antibody production inhibitors
04/30/2008CN100384459C Use of pulse-activating injection in preparing synergetic medicine for treating tumor
04/30/2008CN100384436C Parenteral cisplatin emulsion
04/30/2008CN100384424C Synergistic methods and compositions for treating cancer
04/30/2008CN100384419C Epothilone slow-release implanting composition and use
04/30/2008CN100384415C Preparation method of magnetic nanometer granule containing mitocin-C
04/30/2008CN100384412C Methods and compositions for inhibiting 5 'alpha'-reductase activity
04/30/2008CN100384409C Use of triethylene-tetramine as antitumour auxiliary drug
04/30/2008CN100384399C Temperature controllable heat therapeutic embolizing sponge powder an its preparation process
04/29/2008US7365197 Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines
04/29/2008US7365191 immunology; antitumor agents; viricides; anticancer agents; antiinflammatory agents; oligosaccharde containing glucose, galactose, mannose
04/29/2008US7365172 Cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal side effects; peptide that is derived from a loop or "lollipop" region of transforming growth factor; stimulate hematopoiesis; diabetes, rheumatoid arthritis, lupus, and multiple sclerosis
04/29/2008US7365170 Reagents for regulation of metabolic events, such as those mediated by adiponectin and adiponectin agonists. The invention also provides screening assays for identification of biologically active agents, diagnostic and therapeutic agents
04/29/2008US7365169 T-bet antibodies
04/29/2008US7365159 Plasminogen fragments containing kringle region domains having anti-angiogenic activity and terned angiostatin protein. The plasminogen fragments of the present invention may be used for the treatment of angiogenesis-dependent diseases such as
04/29/2008US7365155 Immunoregulator
04/29/2008US7365089 Triazolo-quinolin derivatives useful as adenosine receptor ligands
04/29/2008US7365081 Antitumor agents
04/29/2008US7365066 Pyrazolopyridine derivatives as pharmaceutical agents
04/29/2008US7365065 Antigonadotrophins; Breast and prostate cancer, endometriosis and benign prostate hyperplasia; regulation of fertility; in-vitro fertilisation; oral administration; inexpensive; 3-Amino-4-chloro-N-[4-chloro-5-(2,3-dihydro-benzo[1,4]oxazine-4-carbonyl)-thiophen-3-ylmethyl]-N-methyl-benzenesulfonamide
04/29/2008US7365064 Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them
04/29/2008US7365054 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
04/29/2008US7364919 Immobilization carbohydrates; calibration; diagnosis; antiinflammatory agents, bactericides
04/29/2008US7364845 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of cancer, psoriasis and nervous system disorders
04/29/2008US7364741 Peptides of human Papilloma virus for use in human T cell response inducing compositions
04/29/2008US7364730 Human K+ channel and prognosing applications thereof
04/29/2008US7364729 Method of inducing a CTL response
04/29/2008US7364726 Pharmaceutical composition for cancer treatment containing cells that express a membrane cytokine
04/29/2008US7364724 Recombinant super-compound interferon
04/29/2008CA2370098C Human beta-trcp protein
04/29/2008CA2343204C Arylsulfonanilide ureas
04/29/2008CA2302445C New taxane derivatives
04/29/2008CA2259960C Down-regulation of dna repair to enhance sensitivity to p53-mediated suppression
04/29/2008CA2177952C Nucleosides and oligonucleotides containing boron clusters
04/29/2008CA2120353C Cell cycle controlling compositions and methods of using same
04/27/2008CA2586614A1 Triterpenes derivatives and uses thereof as antitumor agents or anti-inflammatory agents
04/27/2008CA2571805A1 Tissue targeted antigenic activation of the immune response to cancers
04/24/2008WO2008048577A1 Methods of using 4-phenylaminoquinolines as topical non-steroidal antiinflammatory compounds
04/24/2008WO2008047948A1 Block copolymer for drug complex and pharmaceutical composition
04/24/2008WO2008047925A1 Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
04/24/2008WO2008047914A1 Cancer therapeutic agent comprising anti-hb-egf antibody as active ingredient
04/24/2008WO2008047831A1 Jak inhibitor
04/24/2008WO2008047821A1 Fused heterocyclic compound
04/24/2008WO2008047723A1 Diagnosis and treatment of cancer using anti-ereg antibody
04/24/2008WO2008047574A1 Sensitizer for anticancer agent
04/24/2008WO2008047544A1 Diaryl ketimine derivative
04/24/2008WO2008047473A1 Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
04/24/2008WO2008047307A1 Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
04/24/2008WO2008047082A2 Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
04/24/2008WO2008046985A1 Incorporation of active molecules into microalga
04/24/2008WO2008046982A2 New imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular cdc7
04/24/2008WO2008046909A1 The histone deacetylase inhibitor helminthosporium carbonum toxin for suppressing malignant qualities of neuroblastoma cells
04/24/2008WO2008046802A1 Phenylacetamides useful as protein kinase inhibitors
04/24/2008WO2008046649A1 Rspondins as modulators of angiogenesis and vasculogenesis
04/24/2008WO2008046529A1 Treatment of chemotherapy- or radiotherapy-resistant tumors using an l1 interfering molecule
04/24/2008WO2008046459A1 Treatment of chemotherapy- or radiotherapy-resistant tumors using an l1 interfering molecule
04/24/2008WO2008046407A2 Use of deuterium dioxide for treating hyperproliferative skin diseases
04/24/2008WO2008046307A1 Method for inhibiting cancer using arsenic trioxide
04/24/2008WO2008046299A1 Method for inhibiting cancer using arsenic trioxide
04/24/2008WO2008046251A1 Fusion proteins containing n domain of human calreticulin and human papillomavirus type 16 e6 or e7 and uses thereof
04/24/2008WO2008046242A1 The novel quinazoline derivatives,preparation methods and uses thereof
04/24/2008WO2008046228A1 Compounds for stimulating p-glycoprotein function and uses thereof
04/24/2008WO2008046216A1 Kinase inhibitors and uses thereof
04/24/2008WO2008020456A3 Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof
04/24/2008WO2008020206A3 Fused thiophene derivatives as mek inhibitors
04/24/2008WO2008016660A3 Imidazoacridine compounds for treating leukemias
04/24/2008WO2008015139A3 Inhibitors of zinc proteases thioaryl substituted and their use
04/24/2008WO2008012695A3 Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
04/24/2008WO2008012534A3 Retinoids and small molecules as nrf2 antagonists for use in the treatment of diseases associated with abnormal cell proliferation
04/24/2008WO2008011080A3 Benzo(d) isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine
04/24/2008WO2008001166A3 Process for synthesis of glycomimicking cationic amphiphiles
04/24/2008WO2008000881A9 Glycosylated human alpha interferon muteins, method for obtaining them and use
04/24/2008WO2007149730A3 Inhibitors of akt (protein kinase b)
04/24/2008WO2007112754A3 Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
04/24/2008WO2007084162A3 Sirtuin inhibiting compounds
04/24/2008WO2007075870A3 Processes for taxane derivatives and intermediates useful therein
04/24/2008US20080097117 chemical intermediates for making antiinflammatory agents treating autoimmune disease; 1-[2-(Fluoren-3-yl)ethyl]-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine drug
04/24/2008US20080097102 Aminotetralin-derived urea modulators of vanilloid vr1 receptor
04/24/2008US20080096949 Indazolyl-substituted pyrroline compounds as kinase inhibitors
04/24/2008US20080096947 Polyvinylpyrrolidone or cyclodextrin as a builder, and polysorbate as a wetting agent, are dissolved with imexon in an organic solvent, preferably dimethyl sulfoxide, and lyophylized; lyophilisates are dissolved in aqueous propylene glycol; improved storage stability
04/24/2008US20080096946 Tetramethylation of 3,5-di(cyanomethyl)toluene, oxidation of the 1-methyl group to form an aldehyde, conversion to a Boc-protected hydrazone, reduction to a Boc-protected hydrazine, salt formation, conversion to anastrozole; industrial scale, high yield and purity; anticarcinogenic agent; breast cancer
04/24/2008US20080096920 3-{4-[Bis-(quinolin-8-ylcarbamoylmethyl)-amino]-phenyl}-N-hydroxy-acrylamide; 4-(2-Hydroxycarbamoyl-vinyl)-N,N-bis-phenylcarbamoylmethyl-benzamide; useful in treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, and neurdegenerative disorders
04/24/2008US20080096901 Aminotriazole compounds useful as inhibitors of protein kinases
04/24/2008US20080096899 N-Phenyl-2-Pyrimidine-Amine Derivatives and Process for the Preparation Thereof
04/24/2008US20080096897 water soluble; lower toxicity by photosensitization; anticancer; antitumor; antiinflammatory; arthritis; osteoporosis; ocular abnormal angiogenesis; multiple sclerosis, asthma, atherosclerosis
04/24/2008US20080096889 Histone Deacetylases Inhibitors
04/24/2008US20080096887 Benzene, Pyridine, and Pyridazine Derivatives
04/24/2008US20080096881 Quinazoline Derivatives
04/24/2008US20080096880 Use of imidazo[1,2,4]triazinones which are inhibitors of cGMP-metabolizing phosphodiesterases (PDE I, II and V) to treat cardiovascular disorders, urogenital disorders, prostate hyperplasia, ocular disorders such as glaucoma, optic neuropathy, diabetic gastroparesis, dementia
04/24/2008US20080096879 More potent analogs of FR901464 from Pseudomonas sp. No. 2663 culture and chemical synthesis; anticancer agents; intermediates
04/24/2008US20080096868 [1-(4-methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-o-tolyl-amine for example; protein tyrosine kinase inhibitors; anticancer agents
04/24/2008US20080096864 Partially imatinib-resistant tumors; synergistic; combined packaging; oral administration
04/24/2008US20080096861 Chemical Compounds
04/24/2008US20080096854 Orally administering edible oil homogenized with edible wax and a sterol comprising stigmasterol, campesterol, p-sitosterol, chalinosterol, clionasterol, brassicasterol, alpha -spinasterol, daucosterol, desmosterol, and poriferasterol to treat colorectal, stomach, and/or esophagus cancer
04/24/2008US20080096849 Administering balsalazide with food increases bioavailability of balsalazide and metabolites 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid; label on container recommends to take drug with food; inflammatory bowel disease, radiation enteritis, colon cancer; gastrointestinal disorders
04/24/2008US20080096848 Substituted N-Aryl-9-Oxo-9H-Fluorene-1-Carboxamides and Analogs as Activators of Caspases and Inducers of Apoptosis
04/24/2008US20080096846 Ruthenium complexes with ligands that have a longer hydrolysis time such as azide, isothiocyanate, pyridines, thiolates; thought to bind to DNA after hydrolysis for antitumor effect; pharmacokinetics; ruthenium complex with biphenyl, ethylenediamine, azide and hexafluorophosphide for example
04/24/2008US20080096834 Administering a nucleic acid encoding a trout E-domain peptide or somatomedin as antiproliferative, anticarcinogenic and/or antitumor agent in mammals or fish
04/24/2008US20080096833 Diagnostic drugs and kits; coded for human proto-oncogene Pim-3, an antibody specific thereto; short interence RNA; genetic engineering